Gilead’s logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. Photo: AFP

Did Gilead’s anti-coronavirus drug work or flop in its Wuhan clinical trial? Wall Street analysts are divided in their assessment

  • A report that showed that the drug had not made any significant difference in the fatality or improvement in patients was removed by the World Health Organisation
  • Gilead and scientists involved in the trial dispute how the results should be interpreted. Now Wall Street analysts covering Gilead are weighing in
Topic |   Pharmaceuticals
Gilead’s logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. Photo: AFP
READ FULL ARTICLE